drugset / Trial / NCT00537862

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients

NCT00537862

Phase 4 Completed 200 enrolled Novartis Pharmaceuticals
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) in a cyclosporine microemulsion based regimen with C2 monitoring in de novo kidney transplant recipients

Timeline

Start
2006-05
Primary completion
2007-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Mycophenolate Sodium Unknown

Indications

No indication recorded.